ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion

Journal of Clinical Investigation

Volumn 122, Issue 5, 2012, Pages 1869-1880

  Long, Weiwen ^a   Foulds, Charles E ^a   Qin, Jun ^a,a   Liu, Jian ^a   Ding, Chen ^a   Lonard, David M ^a   Solis, Luisa M ^b   Wistuba, Ignacio I ^b   Tsai, Sophia Y ^a   Tsai, Ming Jer ^a   O'Malley, Bert W ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 6; SERINE; STEROID RECEPTOR COACTIVATOR 3; TRANSCRIPTION FACTOR PEA3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER MODEL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MASS SPECTROMETRY; MMP GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASES; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASE 6; NEOPLASM INVASIVENESS; NEOPLASM TRANSPLANTATION; NUCLEAR RECEPTOR COACTIVATOR 3; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSCRIPTION FACTORS;

EID: 84860598488     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI61492     Document Type: Article

References (39)

1. Coulombe P, Meloche S. Atypical mitogen-activated protein kinases: structure, regulation and functions. Biochim Biophys Acta. 2007;1773(8):1376- 1387. (Pubitemid 47125971)
2. Boulton TG, et al. ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell. 1991;65(4):663-675.
3. Deleris P, Rousseau J, Coulombe P, Rodier G, Tanguay PL, Meloche S. Activation loop phosphorylation of the atypical MAP kinases ERK3 and ERK4 is required for binding, activation and cytoplasmic relocalization of MK5. J Cell Physiol. 2008;217(3):778-788.
4. Schumacher S, et al. Scaffolding by ERK3 regulates MK5 in development. Emb o J. 2004;23(24):4770-4779. (Pubitemid 40069707)
5. Seternes OM, et al. Activation of MK5/PRAK by the atypical MAP kinase ERK3 defines a novel signal transduction pathway. EMBO J. 2004;23(24):4780-4791.
6. Kant S, Schumacher S, Singh MK, Kispert A, Kotlyarov A, Gaestel M. Characterization of the atypical MAPK ERK4 and its activation of the MAPK-activated protein kinase MK5. J Biol Chem. 2006;281(46):35511-35519. (Pubitemid 46043251)
7. Coulombe P, Rodier G, Pelletier S, Pellerin J, Meloche S. Rapid turnover of extracellular signal-regulated kinase 3 by the ubiquitin-proteasome pathway defines a novel paradigm of mitogen-activated protein kinase regulation during cellular differentiation. Mol Cell Biol. 2003;23(13):4542-4558. (Pubitemid 36734745)
8. Julien C, Coulombe P, Meloche S. Nuclear export of ERK3 by a CRM1-dependent mechanism regulates its inhibitory action on cell cycle progression. J Biol Chem. 2003;278(43):42615-42624. (Pubitemid 37310535)
9. Hansen CA, Bartek J, Jensen S. A functional link between the human cell cycle-regulatory phosphatase Cdc14A and the atypical mitogen-activated kinase Erk3. Cell Cycle. 2008;7(3):325-334. (Pubitemid 351366496)
10. Klinger S, Turgeon B, Levesque K, Wood GA, Aagaard-Tillery KM, Meloche S. Loss of Erk3 function in mice leads to intrauterine growth restriction, pulmonary immaturity, and neonatal lethality. Proc Natl Acad Sci U S A. 2009;106(39):16710-16715.
11. Evtimova V, et al. Identification of breast cancer metastasis-associated genes by chip technology. Anticancer Res. 2001;21(6A):3799-3806. (Pubitemid 34229244)
12. Liang B, Wang S, Zhu XG, Yu YX, Cui ZR, Yu YZ. Increased expression of mitogen-activated protein kinase and its upstream regulating signal in human gastric cancer. World J Gastroenterol. 2005; 11(5):623-628. (Pubitemid 40220747)
13. Nambiar S, et al. Signaling networks in cutaneous melanoma metastasis identified by complementary DNA microarrays. Arch Dermatol. 2005; 141(2):165-173. (Pubitemid 40216258)
14. Bhattacharjee A, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98(24):13790-13795. (Pubitemid 33115977)
15. Torres-Arzayus MI, et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell. 2004;6(3):263-274. (Pubitemid 39222039)
16. Zhou HJ, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005;65(17):7976-7983.
17. Xu J, Wu RC, O'Malley BW. Normal and cancerrelated functions of the p160 steroid receptor co-activator (SRC) family. Nat Rev Cancer. 2009;9(9):615-630.
18. Long W, et al. SRC-3Delta4 mediates the interaction of EGFR with FAK to promote cell migration. Mol Cell. 2010;37(3):321-332.
19. Qin L, et al. The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression. Mol Cell Biol. 2008;28(19):5937-5950.
20. Yan J, et al. Steroid receptor coactivator-3/AIB1 promotes cell migration and invasiveness through focal adhesion turnover and matrix metalloproteinase expression. Cancer Res. 2008;68(13):5460-5468.
21. Li LB, Louie MC, Chen HW, Zou JX. Proto-oncogene ACTR/AIB1 promotes cancer cell invasion by up-regulating specific matrix metalloproteinase expression. Cancer Lett. 2008;261(1):64-73.
22. Wu RC, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways. Mol Cell. 2004;15(6):937-949.
23. Oh AS, et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol Cell Biol. 2008;28(21):6580-6593.
24. Yi P, et al. Atypical protein kinase C regulates dual pathways for degradation of the oncogenic coactivator SRC-3/AIB1. Mol Cell. 2008;29(4):465-476. (Pubitemid 351291678)
25. Malovannaya A, et al. Analysis of the human endogenous coregulator complexome. Cell. 2011;145(5):787-799.
26. Cai D, et al. Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation. Cancer Res. 2010;70(16):6477-6485.
27. Wang H, et al. Overexpression and gender-specific differences of SRC-3 (SRC-3/AIB1) immunoreactivity in human non-small cell lung cancer: an in vivo study. J Histochem Cytochem. 2010;58(12):1121-1127.
28. Olson MF, Sahai E. The actin cytoskeleton in cancer cell motility. Clin Exp Metastasis. 2009;26(4):273-287.
29. Deleris P, et al. Activation loop phosphorylation of ERK3/ERK4 by group I p21-activated kinases (PAKs) defines a novel PAK-ERK3/4-MAPK-activated protein kinase 5 signaling pathway. J Biol Chem. 2011;286(8):6470-6478.
30. De la Mota-Peynado A, Chernoff J, Beeser A. Identification of the atypical MAPK Erk3 as a novel substrate for p21-activated kinase (Pak) activity. J Biol Chem. 2011;286(15):13603-13611.
31. Zhao ZS, Manser E. PAK and other Rho-associated kinases - effectors with surprisingly diverse mechanisms of regulation. Biochem J. 2005;386(pt 2):201-214. (Pubitemid 40343777)
32. Beeser A, Jaffer ZM, Hofmann C, Chernoff J. Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors. J Biol Chem. 2005;280(44):36609-36615. (Pubitemid 41587737)
33. Tak H, et al. 14-3-3epsilon inhibits MK5-mediated cell migration by disrupting F-actin polymerization. Cell Signal. 2007;19(11):2379-2387. (Pubitemid 47361692)
34. Kostenko S, Johannessen M, Moens U. PKA-induced F-actin rearrangement requires phosphorylation of Hsp27 by the MAPKAP kinase MK5. Cell Signal. 2009;21(5):712-718.
35. Han SJ, Lonard DM, O'Malley BW. Multi-modulation of nuclear receptor coactivators through posttranslational modifications. Trends Endocrinol Metab. 2009;20(1):8-15.
36. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science. 2004;303(5665):1800-1805. (Pubitemid 38374863)
37. Fidias P, Novello S. Strategies for prolonged therapy in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(34):5116-5123.
38. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-181.
39. Shigematsu H, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97(5):339-346. (Pubitemid 40425952)